减量全脑放疗联合立体定向放射外科治疗1-4个脑转移瘤:在不影响脑肿瘤控制的前提下尽量减少神经认知功能恶化
本研究为多中心前瞻性单臂研究,纳入≤4个脑转移瘤且KPS≥70的患者40例,采用减量全脑放疗(25 Gy/10次)联合立体定向放射外科治疗。6个月远隔脑肿瘤无复发生存率为76.9%,虽未证实非劣效于历史对照(>71%,p=0.16),但全脑肿瘤累积发生率23.0%不劣于历史对照(p=0.774),6个月持续认知下降累积发生率为48.6%。结论认为减量全脑放疗联合立体定向放射外科可能获得与标准剂量全脑放疗联合立体定向放射外科相当的颅内肿瘤控制,并可能降低神经认知下降风险。
要点
- 减量全脑放疗(25 Gy/10次)联合立体定向放射外科治疗≤4个脑转移瘤,6个月远隔脑肿瘤无复发生存率76.9%。
- 6个月全脑肿瘤累积发生率23.0%,不劣于标准剂量全脑放疗联合立体定向放射外科历史对照(p=0.774)。
- 6个月持续认知下降累积发生率为48.6%(定义:≥1项测试>2.0 SD)。
核心结论
- 减量全脑放疗联合立体定向放射外科可能获得与标准剂量全脑放疗联合立体定向放射外科相当的颅内肿瘤控制,并可能降低神经认知下降风险。
研究设计与样本
- 多中心前瞻性单臂研究,纳入≤4个脑转移瘤(增强MRI确认)且KPS≥70的患者,来自7家机构共40例,中位年龄69岁。
- 干预为减量全脑放疗(25 Gy,10次)联合立体定向放射外科。
- 主要终点为6个月远隔脑肿瘤无复发生存率的非劣效性,对照为随机临床试验(JROSG99-1)中标准剂量全脑放疗(30 Gy,10次)联合立体定向放射外科组。
主要发现
- 原发肿瘤为肺者28例,单发脑转移者20例;中位生存时间19.0个月(95%CI:13.8%-27.5%)。
- 6个月远隔脑肿瘤无复发生存率为76.9%(95%CI:59.5%-87.7%),与历史对照相当,但预设非劣效界值(>71%)未能确认(p=0.16)。
- 6个月全脑肿瘤累积发生率(考虑死亡竞争风险)为23.0%(95%CI:11.4-37.1),不劣于历史对照(p=0.774)。
- 6个月持续认知下降累积发生率为48.6%(定义:≥1项测试>2.0 SD)。
关键数值与推荐
- 减量全脑放疗剂量为25 Gy,10次。
- 标准剂量全脑放疗历史对照剂量为30 Gy,10次。
- 主要终点非劣效界值为>71%(6个月远隔脑肿瘤无复发生存率),实际76.9%,p=0.16。
- 6个月全脑肿瘤累积发生率23.0%(95%CI:11.4-37.1),与历史对照比较p=0.774。
- 持续认知下降定义:≥1项测试>2.0 SD,6个月累积发生率48.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 预设非劣效性(>71%)未能确认(p=0.16)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To minimize cognitive decline without increasing brain tumor recurrence (BTR) by reduced-dose whole-brain radiotherapy (RD-WBRT) (25 Gy, 10 fractions) + stereotactic radiosurgery (SRS) in patients with ≤ 4 brain metastases. MATERIALS AND METHODS: Eligible patients with ≤ 4 brain metastases on contrast-enhanced MRI and Karnofsky Performance Status ≥ 70. The primary endpoint was the non-inferiority of BTR at distant sites in the brain (BTR-distant)-free survival at 6 months compared to that of the standard dose (SD)-WBRT (30 Gy, 10 fractions) + SRS arm in a randomized clinical trial (JROSG99-1) of SRS with/without SD-WBRT. Secondary endpoints included BTR at any brain sites (BTR-all) and neurocognitive function assessed by a six-test standardized battery. RESULTS: Forty patients from seven institutions were enrolled (median age 69 years). The primary tumor site was a lung in 28 patients; 20 patients had a solitary brain metastasis. The median survival time was 19.0 months (95 %CI: 13.8 %-27.5 %). The BTR-distant-free survival at 6 months was 76.9 % (59.5 %-87.7 %), which is comparable to that of historical control although predetermined non-inferiority (>71 %) could not be confirmed (p = 0.16). The cumulative incidence of BTR-all at 6 months accounting for the competing risk of death was 23.0 % (11.4-37.1), which was not worse than that of historical control (p = 0.774). The frequency of the cumulative incidence of persistent cognitive decline at 6 months was 48.6 % under the [>2.0 SD in ≥ 1 test] definition. CONCLUSIONS: RD-WBRT may yield comparable intracranial tumor control when combined with SRS, and may reduce the risk of neurocognitive decline compared to that after SD-WBRT.
引用
- Nakano T, Aoyama H, Onodera S, et al. Reduced-dose WBRT combined with SRS for 1-4 brain metastases aiming at minimizing neurocognitive function deterioration without compromising brain tumor control. Clin Transl Radiat Oncol. 2022. PMID: 36199814. doi:10.1016/j.ctro.2022.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。